C WorldWide Group’s Teva Pharmaceuticals TEVA Stock Holding History

C WorldWide Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-326,269	Closed	-$5.74M	–	128
2017 Q3	$5.74M	Buy	326,269 +76,038	+30%	+$1.71M	0.08%	59
2017 Q2	$8.31M	Sell	250,231 -22,819	-8%	-$706K	0.13%	51
2017 Q1	$8.76M	Hold	273,050	–	–	0.15%	47
2016 Q4	$9.9M	Buy	273,050 +8,050	+3%	+$321K	0.19%	43
2016 Q3	$12.2M	Hold	265,000	–	–	0.21%	38
2016 Q2	$13.3M	Sell	265,000 -53,000	-17%	-$2.82M	0.25%	31
2016 Q1	$17M	Hold	318,000	–	–	0.33%	29
2015 Q4	$20.9M	Sell	318,000 -33,500	-10%	-$2.07M	0.37%	30
2015 Q3	$19.8M	Buy	351,500 +115,500	+49%	+$7.49M	0.33%	30
2015 Q2	$13.9M	Buy	236,000 +200,000	+556%	+$12.3M	0.2%	39
2015 Q1	$2.24M	Hold	36,000	–	–	0.03%	80
2014 Q4	$2.07M	Hold	36,000	–	–	0.03%	76
2014 Q3	$1.94M	Buy	+36,000	New	+$1.91M	0.03%	79

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

C WorldWide Group's TEVA Position: Q4 2017 in Review

C WorldWide Group sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 326,269 shares — an estimated $5.74M sold.

C WorldWide Group first reported a position in TEVA in Q3 2014 and held it in 13 quarters. The position peaked at $20.9M in Q4 2015. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

C WorldWide Group reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
C WorldWide Group sold 326,269 Teva Pharmaceuticals shares in Q4 2017, an estimated $5.74M.
C WorldWide Group first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 13 quarters.
C WorldWide Group's Teva Pharmaceuticals position peaked at $20.9M in Q4 2015.
508 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on C WorldWide Group's 13F filing for Q4 2017, filed 7 Feb 2018.